Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages 1466-1471

  Terpos, Evangelos ^a   Christoulas, Dimitrios ^a   Katodritou, Eirini ^a   Bratengeier, Cornelia ^b   Gkotzamanidou, Maria ^a   Michalis, Eurydiki ^a   Delimpasi, Sosana ^a   Pouli, Anastasia ^a   Meletis, John ^a   Kastritis, Efstathios ^a   Zervas, Konstantinos ^a   Dimopoulos, Meletios A ^a  

^a Greek Myeloma Study Group   (Greece)

^b Biomarker Design Forschungs GmbH   (Austria)

Author keywords

bone disease; bortezomib; dickkopf 1; multiple myeloma; osteoblast; osteocyte; sclerostin

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; PARATHYROID HORMONE; SCLEROSTIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; CANCER CLASSIFICATION; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FRACTURE; HUMAN; INTERNATIONAL STAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; BORONIC ACIDS; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 84864144433     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27342     Document Type: Article

References (20)

1. Christoulas D, Terpos E, Dimopoulos MA,. Pathogenesis and management of myeloma bone disease. Expert Rev Hematol 2009; 2: 385-98.
2. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr,. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-94.
3. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E,. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119: 1728-31.
4. Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL,. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010; 87: 99-107.
5. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM,. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005; 15: 928-35.
6. D'Amelio P, Roato I, D'Amico L, Veneziano L, Suman E, Sassi F, Bisignano G, Ferracini R, Gargiulo G, Castoldi F, Pescarmona GP, Isaia GC,. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int, 2011; 22: 2869-77.
7. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E,. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int, in press.
8. Voskaridou E, Christoulas D, Papatheodorou A, Bratengeier C, Plata E, Kaliontzi D, Woloszczuk W, Terpos E,. High circulating levels of sclerostin correlate with bone mineral density in patients with thalassemia and osteoporosis: the role of the Wnt signaling in the pathogenesis of bone loss in thalassemia. Blood 2010; 116: 691 (abstract 1010).
9. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI,. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688-92.
10. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-5.
11. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J,. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005; 19: 1842-4.
12. van Oers RF, van Rietbergen B, Ito K, Hilbers PA, Huiskes R,. A sclerostin-based theory for strain-induced bone formation. Biomech Model Mechanobiol 2011; 10: 663-70.
13. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE,. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-53.
14. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH,. Sclerostin and dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-82.
15. Colucci S, Brunetti G, Oranger A, Mori G, Sardone F, Liso V, Curci P, Miccolis RM, Rinaldi E, Specchia G, Passeri G, Zallone A, et al. Myeloma cells induce osteoblast suppression through sclerostin secretion. Blood 2010; 116: 1221 (abstract 2961).
16. Giuliani N, Storti P, Abeltino M, Bolzoni M, Ferretti M, Laziaretti M, Palma BD, Todoerti K, Martella E, Agnelli L, Neri A, Rizzoli V, et al. In vitro and in vivo evidences of osteocyte involvement in myeloma-induced osteolysis. Blood 2010; 116: 62-3 (abstract 131).
17. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J,. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010; 69: 2152-9.
18. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A,. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004; 126: 686-9.
19. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA,. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010; 21: 1561-2.
20. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones. J Bone Miner Res 2011; 26: 1012-21.